Hepatic function and the cardiometabolic syndrome

Diabetes, Metabolic Syndrome and Obesity

Volumn 6, Issue , 2013, Pages 379-388

  Wiernsperger, Nicolas ^a  

^a INSERM   (France)

Author keywords

Cardiometabolic syndrome; Fatty liver; Insulin resistance; Nonalcoholic liver disease; Pharmacology

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GLITAZONE DERIVATIVE; GLUCOCORTICOID; GLUCOSE 6 PHOSPHATASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN SENSITIZING AGENT; METFORMIN; PREBIOTIC AGENT; PROBIOTIC AGENT; TOLL LIKE RECEPTOR 4;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOMETABOLIC SYNDROME; DISEASE MARKER; ENDOPLASMIC RETICULUM STRESS; FATTY LIVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GEOGRAPHIC DISTRIBUTION; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLYCATION; HEART MUSCLE BLOOD FLOW; HOMEOSTASIS; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTESTINE MUCOSA PERMEABILITY; INTRAABDOMINAL FAT; KUPFFER CELL; LIFESTYLE MODIFICATION; LIPID METABOLISM; LIPID PEROXIDATION; LIVER CELL; LIVER FUNCTION; LIVER METABOLISM; METABOLIC DISORDER; MICROALBUMINURIA; MICROCIRCULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NUTRITIONAL STATUS; OXIDATIVE STRESS; PATHOGENESIS; PREVALENCE; RETINA BLOOD FLOW; REVIEW; SIGNAL TRANSDUCTION;

EID: 84885703063     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S51145     Document Type: Review

References (119)

1. Kotani K, Peroni OD, Minokoshi Y, Boss O, Khan BB. GLUT4 glucose transporters deficiency increases hepatic lipid production and peripheral lipid utilization. J Clin Invest. 2004;114:1666-1675.
2. Kitajima Y, Hyogo H, Sumida Y, et al. The severity of nonalcoholic steatohepatitis is associated with substitution of adipose tissue in skeletal muscle. J Gastroenterol Hepatol. April 12, 2013. [Epub ahead of print.]
3. Grunnet LG, Laurila E, Hansson O, et al. The triglyceride content in skeletal muscle is associated with hepatic but not peripheral insulin resistance in elderly twins. J Clin Endocrinol Metab. 2012;97:4571-4577.
4. Raz I. Viewpoints on the way to a consensus session. Diabetes Care. 2009;32 Suppl 2:S149-S150.
5. Wiernsperger N, Nivoit P, Bouskela E. Obstructive sleep apnea and insulin resistance: a role for microcirculation? Clinics. 2006;61:253-266.
6. Loria P, Lonardo A, Anania F. Liver and diabetes. A vicious circle. Hepatol Res. 2013;43:51-64.
7. Bellentani S, Scaglioni F, Marino M, Bedoni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28:155-161.
8. Levene AP, Goldin RD. The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology. 2012;61: 141-152.
9. Medilla-Santillan R, Lopez-Velasquez JA, Chavez-Tapia N, et al. Hepatic manifestations of metabolic syndrome. Diabetes Metab Res Rev. March 7, 2013. [Epub ahead of print.]
10. Ortiz-Lopez C, Lomonaco R, Orsak B, et al. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care. 2012;35:873-878.
11. Lottenberg AM, Afonso M, Ferrari Lavrador MS, et al. The role of dietary fatty acids in the pathology of metabolic syndrome. J Nutr Biochem. 2012;23:1027-1040.
12. Utzschneider KM, Kahn SE. The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2006;91:4753-4761.
13. Korenblat KM, Fabbrini E, Mohammed BS, Klein S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology. 2008;134:1369-1375.
14. Andre P, Balkau B, Vol S, et al. Gamma-glutamyltransferase activity and development of the metabolic syndrome (IDF definition) in middle-aged men and women. Diabetes Care. 2007;30:2355-2361.
15. Sesti G, Fiorentino TV, Hribal ML, Sciacqua A, Perticone F. Association of hepatic insulin resistance indexes to nonalcoholic fatty liver disease and related biomarkers. Nutr Metab Cardiovasc Dis. February 15, 2013. [Epub ahead of print.]
16. Ding S, Chi MM, Scull BP, et al. High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse. PLoS One. 2010;5:e12191.
17. Schnabl B. Linking intestinal homeostasis and liver disease. Curr Opin Gastroenterol. 2013;29:264-270.
18. Ilan Y. Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis. World J Gastroenterol. 2012;18:2609-2618.
19. Le Roy T, Llopis M, Lepage M, et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut. November 29, 2012. [Epub ahead of print.]
20. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115:1343-1351.
21. Miele L, Marrone G, Lauritano C, et al. Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target. Curr Pharm Des. 2013;19:5314-5324.
22. Stenman LK, Holma R, Eggert A, Korpela R. A novel mechanism for gut barrier dysfunction by dietary fat: epithelial disruption by hydrophobic bile acids. Am J Physiol Gastrointest Liver Physiol. 2013;304: G227-G234.
23. Wiernsperger N, Geloen A, Rapin JR. Fructose and cardiometabolic disorders: the controversy will, and must, continue. Clinics. 2010;65: 729-738.
24. Basaranoglu M, Basaranoglu G, Sabuncu T, Senturk H. Fructose as a key player in the development of fatty liver disease. World J Gastroenterol. 2013;19:1166-1172.
25. Lanaspa MA, Sanchez-Losada LG, Cicherchi C, et al. Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver. PLoS One. 2012;7:e47948.
26. Bremer AA, Mietus-Snyder M, Lustig RH. Toward a unifying hypothesis of metabolic syndrome. Pediatrics. 2012;129:557-570.
27. Mirrakhimov AE, Polotsky VY. Obstructive sleep apnea and non-alcoholic fatty liver disease: is the liver another target? Front Neurol. 2012;3:149.
28. Bjorntorp P, Rosmond R. The metabolic syndrome- a neuroendocrine disorder? Br J Nutr. 2000;83:S49-S57.
29. Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Clinical review: the pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab. 2009;94: 2692-2701.
30. Stalder T, Kirschbaum C, Alexander N, et al. Cortisol in hair and the metabolic syndrome. J Clin Endocrinol Metab. 2013;98:2573-2580.
31. D'Souza AM, Beaudry JL, Szigiato AA, et al. Consumption of a high-fat diet rapidly exacerbates the development of fatty liver disease that occurs with chronically elevated glucocorticoids. Am J Physiol Gastrointest Liver Physiol. 2012;302:G850-G863.
32. Van Cauter E. Sleep disturbances and insulin resistance. Diabet Med. 2011;28:1455-1462.
33. Garaulet M, Engstroem G, Hedblad B. Chronobiological aspects of nutrition, metabolic syndrome and obesity. Adv Drug Deliv Rev. 2010;62:967-978.
34. Vozarova B, Stefan N, Lindsay RS, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002;51:1889-1895.
35. Gomez-Samano MA, Cuevas-Ramos D, Mehta R, Brau-Figueroa H, Meza-Arana CE, Gulias-Herrero A. Association of alanine aminotransferase levels (ALT) with the hepatic insulin resistance index (HIRI): a cross-sectional study. BMC Endocr Disord. 2012;12:16.
36. Hanley AJG, Williams K, Festa A, Wagenknecht LE, D'Agnostino RB Jr, Haffner SM. Liver markers and development of the metabolic syndrome. Diabetes. 2005;331:3140-3147.
37. Ghamar-Chehreh ME, Amini M, Khedmat H, et al. Elevated alanine aminotransferase activity is not associated with dyslipidemias, but related to insulin resistance and higher disease grades in non-diabetic non-alcoholic fatty liver disease. Asian Pac J Trop Biomed. 2012;2: 702-706.
38. Zhang Y, Lu X, Chao M, et al. Positive correlations of liver enzymes with metabolic syndrome including insulin resistance in newly diagnosed type 2 diabetes mellitus. Endocrine. 2010;38:181-187.
39. Ghouri N, Preiss D, Sattar N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology. 2010;52: 1156-1161.
40. Hwang AC, Lin YC, Liu PT, et al. Synergistic effects of gamma glutamyltransferase and obesity on metabolic syndrome, independent of hepatic steatosis. Ann Epidemiol. 2012;32:876-880.
41. Irie M, Sohda T, Iwata K, et al. Levels of the oxidative stress marker gamma-glutamyltranspeptidase at different stages of nonalcoholic fatty liver disease. J Int Med Res. 2012;40:924-933.
42. Lin LY, Kuo HK, Hwang JJ, et al. Serum bilirubin is inversely associated with insulin resistance and metabolic syndrome among children and adolescents. Atherosclerosis. 2009;203:563-568.
43. Kwak MS, Kim D, Chung GE, et al. Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease. Clin Mol Hepatol. 2012;18:383-390.
44. Jenko-Praznikar Z, Petelin A, Jurdana M, Ziberna L. Serum bilirubin levels are lower in overweight asymptomatic middle-aged adults: an early indicator of metabolic syndrome? Metabolism. 2013;62:976-985.
45. Kumar R, Prakash S, Chhabra S, et al. Association of pro-inflammatory cytokines, adipokines and oxidative stress with insulin resistance and non-alcoholic fatty liver disease. Indian J Med Res. 2012;136: 229-236.
46. Videla LA, Rodrigo R, Araya J, Poniachik J. Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease. Trends Mol Med. 2006;12:555-558.
47. Romeo GR, Lee J, Shoelson SE. Metabolic syndrome, insulin resistance and roles of inflammation- mechanisms and therapeutic targets. Arterioscler Thromb Vasc Biol. 2012;32:1771-1776.
48. Tilg H, Moschen AR. Insulin resistance, inflammation and non-alcoholic fatty liver disease. Trends Endocrinol Metab. 2008;19:371-379.
49. Mollica MP, Lionetti L, Putti R, et al. From chronic overfeeding to hepatic injury: role of endoplasmic reticulum stress and inflammation. Nutr Metab Cardiovasc Dis. 2011;21:222-230.
50. Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol. 2009;51:212-223.
51. Lanthier N, Molendi-Coste O, Cani PD, van Rooijen N, Horsmans Y, Leclercq IA. Kupffer cell depletion prevents but has no therapeutic effect on metabolic and inflammatory changes induced by a high-fat diet. FASEB J. 2011;25:4301-4311.
52. Papackova Z, Palenickova E, Dankova H, et al. Kupffer cells ameliorate hepatic insulin resistance induced by high-fat diet rich in monounsaturated fatty acids: the evidence for the involvement of alternatively activated macrophages. Nutr Metab (Lond). 2012;9:22.
53. Hertle E, van Greevenbrock MMJ, Stehouwer CDA. Complement C3: an emerging risk factor in cardiometabolic disease. Diabetologia. 2012;55:881-884.
54. Haap M, Machann J, von Friedeburg C, et al. Insulin sensitivity and liver fat: role of iron load. J Clin Endocrinol Metab. 2011;96:E958-E961.
55. Fujita N, Takei Y. Iron overload in nonalcoholic steatohepatitis. Adv Clin Chem. 2011;55:105-132.
56. Nelson JE, Klintworth H, Kowdley KV. Iron metabolism in nonalcoholic fatty liver disease. Curr Gastroenterol Rep. 2012;14:8-16.
57. Shim JJ. Body iron, serum ferritin and nonalcoholic fatty liver disease. Korean J Hepatol. 2012;18:105-107.
58. Park SK, Ryoo JH, Kim MG, Shin JY. Association of serum ferritin and the development of metabolic syndrome in middle-aged Korean men. Diabetes Care. 2012;35:2521-2526.
59. Valenti L, Swinkels DW, Burdick L, et al. Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2011;21:568-575.
60. Cheung CL, Cheung TT, Lam KS, Cheung BM. High ferritin and low transferrin saturation are associated with pre-diabetes among a national representative sample of US adults. Clin Nutr. December 28, 2012. [Epub ahead of print.]
61. Martinelli N, Traglia M, Campostrini N, et al. Increased serum hepcidin levels in subjects with the metabolic syndrome: a population study. PLoS One. 2012;7:e48250.
62. Li JJ, Meng X, Zhang C, et al. Hepcidin destabilizes atherosclerootic plaque via overactivating macrophages after erythrophagocytosis. Arterioscler Thromb Vasc Biol. 2012;32:1158-1166.
63. Tsuchiya H, Ebata Y, Sakabe T, et al. High fat, high fructose diet induces hepatic iron overload via a hepcidin-independent mechanism prior to the onset of liver steatosis and insulin resistance in mice. Metabolism. 2013;62:62-69.
64. Rana JS, Nieuwdorp M, Jukema JW, Kastelein JJ. Cardiovascular metabolic syndrome - an interplay of obesity, inflammation, diabetes and coronary heart disease. Diabetes Obes Metab. 2007;9:218-232.
65. Calori G, Lattuada G, Ragogna F, et al. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology. 2011;54: 145-152.
66. Voulgari C, Tentolouris N, Dilaveris P, Tousoulis D, Katsilambros N, Stefanadis C. Increased heart failure risk in normal-weight people with metabolic syndrome compared with metabolically healthy obese individuals. J Am Coll Cardiol. 2011;58:1343-1350.
67. Valentová M, von Haehling S, Doehner W, Murín J, Anker SD, Sandek A. Liver dysfunction and its nutritional implications in heart failure. Nutrition. 2013;29:370-378.
68. Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J. 2012;33:1190-1200.
69. Nakamori S, Onihsi K, Nakajima H, et al. Impaired myocardial perfusion reserve in patients with fatty liver disease assessed by quantitative myocardial perfusion magnetic resonance imaging. Circ J. 2012;76:2234-2240.
70. Sciacqua A, Marini MA, Hribal ML, et al. Association of insulin resistance indexes to carotid intima-media thickness. PloS One. 2013;8:e53968.
71. Reinehr T, Wunsch R, de Sousa G, Toschke AM. Relationship between metabolic syndrome definitions for children and adolescents and intima-media thickness. Atherosclerosis. 2008;199:193-200.
72. Kim HC, Kim DJ, Huh KB. Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. Atherosclerosis. 2009;204:521-525.
73. Colak Y, Senates E, Yesil A, et al. Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine. 2013;43:100-107.
74. Sookoian S, Pirola CJ. Systems biology elucidates common pathogenic mechanisms between nonalcoholic and alcoholic-fatty liver disease. PLoS One. 2013;8:e58895.
75. Hallsworth K, Hoolingsworth KG, Thoma C, et al. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. J Hepatol. 2013;58:757-762.
76. Gutfreund S, Izkhakov E, Pokroy R, et al. Retinal blood flow velocity in metabolic syndrome. Graefes Arch Clin Exp Ophthalmol. 2013;251: 1507-1513.
77. Barac A, Wang H, Shara NM, et al. Markers of inflammation, metabolic risk factors and incident heart failure in American Indians: the Strong Heart Study. J Clin Hypertens (Greenwich). 2012;14:13-19.
78. Jung CH, Yu JH, Bae SJ, et al. Serum gamma-glutamyltransferase is associated with arterial stiffness in healthy individuals. Clin Endocrinol. 2011;75:328-334.
79. Kozakova M, Palombo C, Eng MP, et al. Fatty liver index, gamma-glutamyltransferase and early carotid plaques. Hepatology. 2012;55: 1406-1415.
80. Vanni E, Bugianesi E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis. 2010;42:320-330.
81. Shimabukuro M, Kozuka C, Taira S, et al. Ectopic fat deposition and global cardiometabolic risk: new paradigm in cardiovascular medicine. J Med Invest. 2013;60:1-14.
82. Ibrahim MA, Kelleni M, Geddaway A. Nonalcoholic fatty liver disease: current and potential therapies. Life Sci. 2012;92:114-118.
83. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 2012;55:885-904.
84. Karnchanasorn R, Ou HY, Chuang LM, Chiu KC. Insulin resistance is not necessarily an essential element of metabolic syndrome. Endocrine. 2012;43:92-99.
85. Paredes AH, Torres DM, Harrison SA. Treatment of nonalcoholic fatty liver disease: role of dietary modification and exercise. Clin Liver Dis. 2012;1:116-117.
86. Agius L. High carbohydrate diets induce hepatic insulin resistance to protect the liver from substrate overload. Biochem Pharmacol. 2013;85:306-312.
87. Natali A, Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia. 2006;49:434-441.
88. Radziuk J, Bailey CJ, Wiernsperger N, Yudkin JS. Metformin and its liver targets in the treatment of type 2 diabetes. Curr Drug Targets Immune Endocr Metabol Disord. 2003;3:151-169.
89. Gunton JE, Delhanty PJD, Takahashi SI, Baxter RC. Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin receptor substrate 2. J Clin Endocrinol Metab. 2003;88:1323-1332.
90. Song S, Andrikopoulos S, Filippis C, Thorburn AW, Khan D, Proietto J. Mechanism of fat-induced hepatic gluconeogenesis: effect of metformin. Am J Physiol Endocrinol Metab. 2001;281:E275-E282.
91. Mithieux G, Guignot L, Bordet JC, Wiernsperger N. Intrahepatic mechanisms underlying the effect of metformin in decreasing basal glucose production in rats fed a high fat diet. Diabetes. 2002;51: 139-143.
92. Pasarin M, Abraldes JG, Rodriguez-Vilarrupla A, et al. Insulin resistance and liver microcirculation in a rat model of early NAFLD. J Hepatol. 2011;55:1095-1102.
93. Srividhya S, Anuradha CV. Metformin improves liver antioxidant potential in rats fed a high fructose diet. Asia Pac J Clin Nutr. 2002;11: 319-322.
94. Spruss A, Kanuri G, Stahl C, Bischoff SG, Bergheim I. Metformin protects against the development of fructose-induced steatosis in mice: role of the intestinal barrier function. Lab Invest. 2012;92: 1020-1032.
95. Baret G, Peyronnet J, Grassi-Kassisse D, Dalmaz Y, Wiernsperger N, Géloën A. Increased intraabdominal adipsoe tissue mass in fructose fed rats: correction by metformin. Exp Clin Endocrinol Diabetes. 2002;110:298-303.
96. Shyangdan D, Clar C, Ghouri N, et al. Insulin sensitizers in the treatment of non-alcoholic fatty liver disease: a systematic review. Health Technol Assess. 2011;15:1-110.
97. Garinis GA, Fruci B, Mazza A. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int J Obes. 2010;34:1255-1264.
98. Sofer E, Boaz M, Matas Z, Mashavi M, Shargorodsky M. Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial. Metabolism. 2011;60:1278-1284.
99. Wiernsperger NF, Bouskela E. Microcirculation in insulin resistance and diabetes: more than just a complication. Diabetes Metab. 2003; 29 Suppl 6:77-87.
100. Boettcher E, Csako G, Pucino F, Wesley R, Loomba R. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2012;35:66-75.
101. Phielix E, Szendrooedi J, Roden M. The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact. Trends Pharmacol Sci. 2011;32:607-616.
102. Tiikkainen M, Häkkinen AM, Korsheninnikova E, Nyman T, Mäkimattila S, Yki-Järvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes. 2004;53:2169-2176.
103. Retnakaran R, Ye C, Hanley AJ, Harris SB, Zinman B. Discordant effects on central obesity, hepatic insulin resistance, and alanine aminotransferase of low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance. Diabetes Obes Metab. 2012;14:91-93.
104. Carulli L, Maurantonio M, Hebbard L, Baldelli E, Loria P, George J. Classical and innovative insulin sensitizing drugs for the prevention and treatment of NAFLD. Curr Pharm Des. 2013;19:5280-5296.
105. Lonardo A, Loria P. If steatosis is the atherosclerosis of the liver, are statins the "aspirin" for steatosis? Dig Liver Dis. 2012;44:451-452.
106. Preiss D, Sattar N. Statins and the risk of new-onset diabetes: a review of recent evidence. Curr Opin Lipidol. 2011;22:460-466.
107. Lirussi F, Azzalini L, Orando S, Orlando R, Angelico F. Antioxidant supplements for non alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev. 2007;24: CD004996.
108. Musso G, Anty R, Petta S. Antioxidant therapy and drugs interfering with lipid metabolism: could they be effective in NAFLD patients? Curr Pharm Des. 2013;19:5297-5313.
109. Turner N, Kowalski GM, Leslie SJ, et al. Distinct patterns of tissue-specific lipid accumulation during the induction of insulin resistance in mice by high-fat feeding. Diabetologia. 2013;56:1638-1648.
110. Lee YS, Li P, Huh JY, et al. Inflammation is necessary for long term but not short-term high fat diet-induced insulin resistance. Diabetes. 2011;60:2474-2483.
111. Hirabara SM, Gorjao R, Vinolo MA, Rodrigues AC, Nachbar RT, Curi R. Molecular targets related to inflammation and insulin resistance and potential interventions. J Biomed Biotechnol. 2012;2012:379024.
112. Iacono A, Raso G, Canani RB, et al. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J Nutr Biochem. 2011;22:699-711.
113. Vajro P, Mandato C, Veropalumbo C, De Micco I. Probiotics: a possible role in treatment of adult and pediatric non alcoholic fatty liver disease. Ann Hepatol. 2013;12:161-163.
114. Park DY, Ahn YT, Huh CS, et al. Dual probiotic strains suppress high fructose induced metabolic syndrome. World J Gastroenterol. 2013;19:274-283.
115. Delzenne NM, Neyrinck AM, Cani PD. Gut microbiota and metabolic disorders: how prebiotics can work? Br J Nutr. 2013;109:S81-S85.
116. Barchetta I, Angelico F, Del Ben M, et al. Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med. 2011;9:85.
117. Eliades M, Spyrou E, Agrawal N, et al. Meta-analysis: vitamin D and non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2013;38: 246-254.
118. Rhee EJ, Kim MK, Park SE, et al. High serum vitamin D levels reduce the risk for nonalcoholic fatty liver disease in healthy men independent of metabolic syndrome. Endocr J. 2013;60:743-752.
119. Nakajima K. Multidisciplinary pharmacotherapeutic options for nonalcoholic fatty liver disease. Int J Hepatol. 2012;2012:950693.